Introduction: Glioma is a common primary solid brain tumor with high incidence and poor prognosis. Biochanin A (bioA), an active component of traditional Chinese medicine, has potential therapeutic effects on it, but its mechanism remains unclear. This study aimed to clarify its mechanism via a multi-omics strategy. Methods: A multi-omics integration approach was adopted, which combined single-cell RNA sequencing, in vitro experiments, the construction of a Glutathione S-transferase P1 (GSTP1)-based prognostic model, and analyses of immune infiltration and drug sensitivity to evaluate its clinical value. Results: C2 CENPF⁺ tumor cells were specifically expressed in recurrent gliomas and associated with the bioA pathway. GSTP1 was the key target gene of bioA; its high expression was related to poor prognosis, and its knockout could inhibit glioma progression. The GSTP1-based prognostic model had excellent predictive efficiency. Discussion: BioA may exert anti-glioma effects by regulating GSTP1, providing theoretical support for its clinical application and a new therapeutic target for glioma.
No takes yet. Share an insight, caveat, or question.
Chai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: